The efficacy of therapeutic
antibodies that induce antibody-dependent cellular cytotoxicity can be improved by reduced fucosylation. Consequently, fucosylation is a critical product attribute of
monoclonal antibodies produced as
protein therapeutics. Small molecule fucosylation inhibitors have also shown promise as potential
therapeutics in animal models of
tumors,
arthritis, and
sickle cell disease. Potent small molecule metabolic inhibitors of cellular
protein fucosylation, 6,6,6-trifluorofucose per-O-
acetate and 6,6,6-trifluorofucose (fucostatin I), were identified that reduces the fucosylation of recombinantly expressed
antibodies in cell culture in a concentration-dependent fashion enabling the controlled modulation of
protein fucosylation levels. 6,6,6-Trifluorofucose binds at an allosteric site of
GDP-mannose 4,6-dehydratase (GMD) as revealed for the first time by the X-ray cocrystal structure of a bound allosteric GMD inhibitor. 6,6,6-Trifluorofucose was found to be incorporated in place of
fucose at low levels (<1%) in the
glycans of recombinantly expressed
antibodies. A fucose-1-phosphonate analog, fucostatin II, was designed that inhibits fucosylation with no incorporation into antibody
glycans, allowing the production of afucosylated
antibodies in which the incorporation of non-native
sugar is completely absent-a key advantage in the production of therapeutic
antibodies, especially
biosimilar antibodies. Inhibitor structure-activity relationships, identification of cellular and inhibitor metabolites in inhibitor-treated cells,
fucose competition studies, and the production of recombinant
antibodies with varying levels of fucosylation are described.